Looking to buy FOX-04 for laboratory senescence research? FOX-04, short for FOXO4 D-Retro-Inverso, is a synthetic research peptide designed to interfere with the interaction between the FOXO4 transcription factor and the p53 tumour-suppressor protein.<\/p>\n
This protein interaction has been investigated for its role in supporting the survival of certain senescent cells. Senescent cells have permanently stopped dividing but may remain metabolically active and release signalling molecules associated with tissue ageing and inflammatory processes.<\/p>\n
In a landmark 2017 preclinical study led by researchers affiliated with Erasmus University Medical Center Rotterdam, FOXO4-DRI preferentially reduced the viability of senescent cells by disrupting FOXO4\u2013p53 binding. This promoted the relocation of active p53 and initiated apoptosis in the senescent cells studied. Control cells were less affected under the specific experimental conditions used.<\/p>\n
Peptides Divas supplies FOXO4-DRI in a 10 mg format as a stable lyophilised powder. Each batch is accompanied by batch-specific analytical documentation.<\/p>\n
Dette produkt er udelukkende beregnet til laboratorieforskningsform\u00e5l. Det er ikke beregnet til human eller veterin\u00e6r brug.<\/strong><\/p>\n FOXO4-DRI is studied as an experimental senolytic peptide. In preclinical cell models, it has been shown to compete with FOXO4 for p53 binding, promoting p53 relocation from the nucleus and activating apoptosis-associated pathways in certain senescent cells.<\/p>\n These findings are model-dependent and should not be interpreted as evidence that FOXO4-DRI targets every type of senescent cell.<\/p>\n FOXO4 er en transkriptionsfaktor involveret i cellul\u00e6re stressresponser, homeostase og regulering af celledeling. I de unders\u00f8gte senescentcellemodeller hjalp FOXO4 med at bevare p53 i cellekernen. FOXO4-DRI blev designet til at interferere med denne interaktion og frigive p53 fra disse nukleare komplekser.<\/p>\n I musemodeller var eksperimentel FOXO4-DRI-administration forbundet med forbedringer i udvalgte m\u00e5linger af v\u00e6vshomeostase, herunder mark\u00f8rer relateret til nyrefunktion, pelsdensitet og fysisk aktivitet. Disse resultater blev opn\u00e5et hos dyr og kan ikke direkte ekstrapoleres til mennesker.<\/p>\n FOXO4-DRI uses a D-retro-inverso design in which D-amino acids are arranged in reverse sequence order. This design is commonly investigated as a method of preserving functional side-chain orientation while increasing resistance to proteolytic degradation compared with corresponding conventional L-peptides.<\/p>\n The exact stability and performance of an individual batch depend on its composition, handling and experimental conditions.<\/p>\n Some senescent cells produce a collection of inflammatory cytokines, growth factors and proteases known as the senescence-associated secretory phenotype, or SASP.<\/p>\n By investigating the selective removal of senescent cells, researchers may study whether FOXO4-DRI influences SASP-related signalling and inflammatory processes in controlled experimental models. This remains a preclinical research field and is not an established clinical application.<\/p>\n Hver FOXO4-DRI-batch leveres med et analysecertifikat. Afh\u00e6ngigt af den tilg\u00e6ngelige batchdokumentation kan den analytiske testning omfatte:<\/p>\n Se altid analysecertifikatet for de n\u00f8jagtige specifikationer og analyseresultater for den leverede batch.<\/p>\n FOXO4-DRI 10 mg leveres udelukkende til kontrolleret videnskabelig forskning og laboratorieforskning. Det er ikke et l\u00e6gemiddel, kosttilskud eller kosmetisk produkt og er ikke godkendt til menneskelig konsum, terapeutiske anvendelser, klinisk brug eller veterin\u00e6r brug.<\/p>","protected":false},"excerpt":{"rendered":" Looking to buy FOXO4-DRI for laboratory senescence research? FOXO4-DRI, short for FOXO4 D-Retro-Inverso, is a synthetic research peptide designed to interfere with the interaction between the FOXO4 transcription factor and the p53 tumour-suppressor protein.<\/p>\n This protein interaction has been investigated for its role in supporting the survival of certain senescent cells. Senescent cells have permanently stopped dividing but may remain metabolically active and release signalling molecules associated with tissue ageing and inflammatory processes.<\/p>\n In a landmark 2017 preclinical study led by researchers affiliated with Erasmus University Medical Center Rotterdam, FOXO4-DRI preferentially reduced the viability of senescent cells by disrupting FOXO4\u2013p53 binding. This promoted the relocation of active p53 and initiated apoptosis in the senescent cells studied. Control cells were less affected under the specific experimental conditions used.<\/p>\n Peptides Divas supplies FOXO4-DRI in a 10 mg format as a stable lyophilised powder. Each batch is accompanied by batch-specific analytical documentation.<\/p>\n Dette produkt er udelukkende beregnet til laboratorieforskningsform\u00e5l. Det er ikke beregnet til human eller veterin\u00e6r brug.<\/strong><\/p>","protected":false},"featured_media":741,"comment_status":"open","ping_status":"closed","template":"","meta":{"_acf_changed":false,"nf_dc_page":"","om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0},"product_brand":[],"product_cat":[34],"product_tag":[46],"class_list":["post-740","product","type-product","status-publish","has-post-thumbnail","product_cat-recovery-repair","product_tag-10-mg","first","instock","shipping-taxable","purchasable","product-type-simple"],"acf":[],"yoast_head":"\nFOXO4-DRI Produktspecifikationer<\/h2>\n
\n\n
\n \nSpecifikation<\/th>\n Detaljer<\/th>\n<\/tr>\n<\/thead>\n \n Produktnavn<\/td>\n FOXO4-DRI<\/td>\n<\/tr>\n \n Fulde navn<\/td>\n FOXO4 D-Retro-Inverso peptid<\/td>\n<\/tr>\n \n Bel\u00f8b<\/td>\n 10 mg pr. h\u00e6tteglas<\/td>\n<\/tr>\n \n Forskningskategori<\/td>\n Cellul\u00e6r senescens og senolytisk forskning<\/td>\n<\/tr>\n \n Unders\u00f8gt mekanisme<\/td>\n Forstyrrelse af FOXO4-p53 proteininteraktionen<\/td>\n<\/tr>\n \n Renhed<\/td>\n \u226599,5% ved HPLC<\/td>\n<\/tr>\n \n Form<\/td>\n Fryset\u00f8rret pulver<\/td>\n<\/tr>\n \n Peptiddesign<\/td>\n D-retro-invers struktur<\/td>\n<\/tr>\n \n Opbevaring<\/td>\n Opbevares ved \u221220\u00b0C, beskyttet mod lys og fugt<\/td>\n<\/tr>\n \n Dokumentation<\/td>\n Batchspecifik analysecertifikat<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n Relevansen af videnskabelig forskning<\/h2>\n
Forskning i senescentceller<\/h3>\n
FOXO4-p53-interaktion<\/h3>\n
Aldringsbiologisk forskning<\/h3>\n
D-Retro-Inverso Peptide Design<\/h3>\n
SASP og inflammationsforskning<\/h3>\n
Kvalitetssikring<\/h2>\n
\n
Kun til brug for forskning<\/h2>\n
FOXO4-DRI 10 mg \u2013 Senolytic Research Peptide<\/h1>\n